Rachit Kumar
Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Rachit Kumar

Radiation Oncology
Johns Hopkins Medicine
Sibley Memorial Hospital
5255 Loughboro Road Northwest, 
Washington, DC 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
17 Years of Experience
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Johns Hopkins Medicine
Sibley Memorial Hospital
5255 Loughboro Road Northwest, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

"Dr. Rachit Kumar is a radiation oncologist specializing in genitourinary and gastrointestinal cancers. He is dedicated to patient-centered care, finding the most effective outcome for each patient and using the latest advances to minimize treatment time and side-effects. Dr. Kumar is frequently published in peer-reviewed journals on new methods of radiation therapy and the benefits to patient outcomes. He is a member of the Johns Hopkins Kimmel Cancer Center and treats patients at both Sibley Memorial Hospital and Suburban Hospital. Selected Publications Kumar R, Tchelebi LT, Anker CJ, Sharma N, Bianchi NA, Dragovic J, Goodman KA, Herman JM, Jiang Y, Jones WE, Kenney TJ, Lee P, Kundranda MK, Russo S, Small W, Suh WW, Yee N, and Jabbour SK. “American Radium Society (ARS) Appropriateness Use Criteria (AUC) for Loco-Regional Gastric Adenocarcinoma: Systemic Review and Guidelines.” American Journal of Clinical Oncology. 2022 Sep 1;45(9):391-402. Rooney MK, Traube B, Khan MK, Kumar R, and Walker GV. “Factors associated with image guided radiation therapy image rejection in a multi-site institution.” JCO Oncology Practice. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, and Kuban DA. “Contemporary Prostate Cancer Treatment Choices in Multidisciplinary Clinics Referenced to National Trends.” Cancer. Tang C, Lei X, Smith GL, Pan HY, Hoffman K, Kumar R, Chapin BF, Shih YC, Frank SJ, and Smith BD. ""Influence of Geography on Prostate Cancer Treatment Coice: An Analysis of the National Medicare Database."" International Journal of Radiation Oncology Biology Physics. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Aparicio A, Zurita-Saavedra A, Chun S, Reddy J, Choi S, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Tu SM, Pilie P, Kovitz C, Kumar R, Roberts T, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn and PG. “Addition of local consolidative therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): a multicenter randomized phase II basket trial.” JAMA Oncology.".

Dr. Kumar is rated as an Experienced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, and Prostate Cancer.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Cholangiocarcinoma (Bile Duct Cancer).

Graduate Year
2009
Residency
Johns Hopkins University School of Medicine, Radiation Oncology, 2014
Specialties
Radiation Oncology
Licenses
Radiology in DC
Board Certifications
American Board Of Radiology
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Sibley Memorial Hospital
5255 Loughboro Road Northwest, Washington, DC 20016
Call: 410-502-8000
Other Locations
Johns Hopkins Health Care & Surgery Center — Bethesda
6420 Rockledge Drive, Suite 1200, Bethesda, MD 20817
Call: 410-502-8000
Sibley Memorial Hospital
5255 Loughboro Road Northwest, Washington, DC 20016
Call: 410-502-8000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2/Phase 3
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Other, Drug
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: September 23, 2024
Intervention Type: Drug
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials
Similar Doctors
Jeffrey Meyer
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Jeffrey Meyer
Radiation Oncology
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Jeffrey Meyer
Radiation Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg Building, Floor-L2, Weinberg Building, Floor-L2, 
Baltimore, MD 
 (1.2 miles away)
410-502-8000
Languages Spoken:
English
See accepted insurances

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Akshar N. Patel
Radiation Oncology
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Akshar N. Patel
Radiation Oncology

University Of Maryland Radiation Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-6080
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Akshar Patel is a Radiation Oncologist in Baltimore, Maryland. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pleuropulmonary Blastoma, ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Patel is currently accepting new patients.

Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Keith R. Unger
Radiation Oncology
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Keith R. Unger
Radiation Oncology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Unger is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Unger is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Anal Cancer, and Adult Soft Tissue Sarcoma. Dr. Unger is currently accepting new patients.

VIEW MORE CHOLANGIOCARCINOMA (BILE DUCT CANCER) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
    • Distinguished
    • Pancreatic Cancer
      Dr. Kumar is
      Distinguished
      . Learn about Pancreatic Cancer.
      See more Pancreatic Cancer experts
    • Advanced
    • Familial Pancreatic Cancer
      Dr. Kumar is
      Advanced
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Familial Prostate Cancer
      Dr. Kumar is
      Advanced
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Glioma
      Dr. Kumar is
      Advanced
      . Learn about Glioma.
      See more Glioma experts
    • Lung Cancer
      Dr. Kumar is
      Advanced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Metastatic Brain Tumor
      Dr. Kumar is
      Advanced
      . Learn about Metastatic Brain Tumor.
      See more Metastatic Brain Tumor experts
    • Pancreatoblastoma
      Dr. Kumar is
      Advanced
      . Learn about Pancreatoblastoma.
      See more Pancreatoblastoma experts
    View All 8 Advanced Conditions
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Kumar is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Kumar is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Kumar is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Angiosarcoma
      Dr. Kumar is
      Experienced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Astrocytoma
      Dr. Kumar is
      Experienced
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Kumar is
      Experienced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.